Improving Flexibility and Quality of Life for Your Patients: A Must?

Slides:



Advertisements
Similar presentations
Medical Management for BPH: The Role of Combination Therapy
Advertisements

Pascal Rischmann  European Urology Supplements 
Prostate Cancer 2008: Challenges in Diagnosis and Management
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Volume 53, Issue 5, Pages (May 2008)
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Prostate Cancer Epidemic in Sight?
Volume 62, Issue 6, Pages (December 2012)
Bladder Cancer: A Major Public Health Issue
What is New in Bladder Cancer Diagnosis and Management?
Back to the Future: Introduction and Conclusions
What is New in Hormone Therapy for Prostate Cancer in 2007?
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Management: What Does the Future Hold?
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
An Update of Current Practice in Hypospadias Surgery
Richard C. Harkaway  European Urology Supplements 
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
The Importance of Testosterone Control in Prostate Cancer
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Optimal Testosterone Control and Eligard®
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Pharmacotherapy in Stress and Mixed Incontinence
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Christian Stief  European Urology Supplements 
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer 2008: Challenges in Diagnosis and Management
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Richard Berges  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Profile of Silodosin European Urology Supplements
Bob Djavan  European Urology Supplements 
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease  Tetsuro Tsujimoto, Hiroshi Kajio 
Highlighting Unmet Needs: Real Patients, Difficult Choices
Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Management of Prostate Cancer: Global Strategies
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Manfred Wirth, Peter Iversen, David McLeod, William See 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Counselling of the Prostate Cancer Patient as a Whole Person
Joaquim Bellmunt  European Urology Supplements 
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Epidemiology and Demographics of Prostatitis
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Presentation transcript:

Improving Flexibility and Quality of Life for Your Patients: A Must? Axel Heidenreich  European Urology Supplements  Volume 8, Issue 12, Pages 857-862 (December 2009) DOI: 10.1016/j.eursup.2009.09.004 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Rate of incident coronary heart disease, myocardial infarction, and sudden cardiac death in prostate cancer patients receiving androgen-deprivation therapy (ADT) or no treatment [12]. European Urology Supplements 2009 8, 857-862DOI: (10.1016/j.eursup.2009.09.004) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 The median percent decrease from baseline in hot flush frequency and hot flush score after 4 wk of treatment with placebo or gabapentin 300, 600, or 900mg/d [19]. European Urology Supplements 2009 8, 857-862DOI: (10.1016/j.eursup.2009.09.004) Copyright © 2009 European Association of Urology Terms and Conditions